<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228679</url>
  </required_header>
  <id_info>
    <org_study_id>0309-19-RMB</org_study_id>
    <nct_id>NCT04228679</nct_id>
  </id_info>
  <brief_title>Erbium Laser for Treatment of Vaginal Laxity.</brief_title>
  <official_title>The Affect of Erbium Laser Treatments on Vaginal Laxity in Female Pre-menopausal Female Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with a primary complaint of vaginal laxity visiting a sexual dysfunction clinic at a
      tertiary medical center will undergo randomization to either a series of 3 laser treatments
      or 3 sham treatments, and the effect of these treatments will be measured by several
      validated questionaires and by means of gynecological examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suffering from vaginal laxity as a primary sexual dysfunction complaint will be
      recruited, sign an informed consent and will receive a thorough explanation regarding the
      side effects and possible beneficial affects the laser treatments may bestow.

      Patients will undergo randomization to either a series of 3 laser treatments or 3 sham
      treatments, and the effect of these treatments will be measured by several validated
      questionaires and by means of gynecological examination.

      Follow up after treatment cessation will be for 12 months post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Female sexual function index.</measure>
    <time_frame>From recruitment up to 15 months.</time_frame>
    <description>Changes in the female sexual function index scores pre- and post-treatment. Minimal score is 2, maximal score is 36. Thee higher the score, the improved the sexual function is.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic floor disability index.</measure>
    <time_frame>From recruitment up to 15 months.</time_frame>
    <description>Changes in the pelvic floor disability index scores pre- and post-treatment. Minimal score is 0, maximal score is 300. The higher the score, the improved the worse pelvic floor dysfunction is.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal laxity questionnaire.</measure>
    <time_frame>From recruitment up to 15 months.</time_frame>
    <description>Changes in the vaginal laxity questionnaire scores pre- and post-treatment. Minimal score is 1, maximal score is 7. The lower the score, the worse vaginal laxity is.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pelvic muscle strength.</measure>
    <time_frame>From recruitment up to 15 months.</time_frame>
    <description>Changes in the pelvic muscle strength scores pre- and post-treatment. Minimal score is 0, maximal score is 15. The higher the score, the higher muscle strength is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of improvement.</measure>
    <time_frame>From recruitment up to 15 months.</time_frame>
    <description>Changes in the patient global impression of improvement scores pre- and post-treatment. Minimal score is 1, maximal score is 7. The higher the score, the higher the subjective improvement is.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Erbium laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with vaginal laxity treated with real laser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham laser treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Women with vaginal laxity treated with sham laser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erbium laser</intervention_name>
    <description>Erbium laser device</description>
    <arm_group_label>Erbium laser treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Laser</intervention_name>
    <description>Sham laser device</description>
    <arm_group_label>Sham laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women.

          -  Women with vaginal laxity as a primary complaint.

        Exclusion Criteria:

          -  Vaginal bleeding of unknown source.

          -  Repeated vaginal infections.

          -  Known or suspected cervical pre-malignant neoplasia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Lauterbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam healthcare campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roy Lauterbach, MD</last_name>
    <phone>+972-52-9432416</phone>
    <email>r_lauterbach@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Lauterbach, MD</last_name>
      <phone>0529432416</phone>
      <email>r_lauterbach@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>ROY LAUTERBACH MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

